Canton, MI — December 2, 2025 — TrialAssure, a global leader in clinical trial transparency, disclosure, and data-sharing technology, announced that Chris Hurley, MBA, an esteemed data science expert with more than 35 years of experience in clinical data workflows, has joined its Advisory Leadership Team to strengthen the company’s data strategy, innovation roadmap, and next-generation analytics capabilities. Hurley, former Director of Data Science at MMS and current Americas Director for PHUSE, brings a rare blend of technical expertise, regulatory understanding, and cross-functional leadership to TrialAssure as the company expands its footprint across the pharmaceutical, biotech, and clinical research sectors.
Science Significance
Hurley’s appointment underscores the growing importance of data science, machine learning, and automation in enabling smarter, faster clinical research decisions. His background in SAS programming, statistical workflows, and model-informed data processes equips TrialAssure with deeper scientific insight as it advances tools for clinical data anonymization, disclosure automation, and AI-assisted content generation. By bridging programming, statistics, and operational science, Hurley enhances TrialAssure’s ability to develop AI Enabled, Human Driven™ technologies that support reproducible, high-quality scientific outputs across the drug development lifecycle. His advisory role strengthens scientific innovation in areas where clinical research demands accuracy, transparency, and data defensibility.
Regulatory Significance
TrialAssure’s mission is rooted in global clinical trial disclosure compliance, and Hurley’s extensive regulatory experience bolsters the company’s capabilities in navigating EMA, FDA, and international transparency mandates. His decades of involvement in regulated data handling provide critical guidance as the industry embraces AI and automated systems under strict expectations for traceability, validation, and audit readiness. TrialAssure’s tools already support document anonymization, compliance tracking, and disclosure workflows, and Hurley’s expertise will help ensure that innovations align with evolving standards for data privacy, submission quality, and responsible AI use in clinical trial reporting. His leadership enables TrialAssure to strengthen its regulatory alignment while expanding advanced compliance solutions for global sponsors.
Business Significance
Advertisement
Hurley’s addition is a strategic milestone for TrialAssure during a period of accelerated demand for AI-powered clinical technologies, transparency platforms, and data governance solutions. His ability to translate complex technical processes into scalable, business-ready strategies supports TrialAssure’s growth trajectory as biopharmaceutical companies seek robust tools to manage rising disclosure requirements, decentralized trial data, and global compliance pressures. His industry reputation and long-standing collaborations across sponsor and CRO environments provide TrialAssure with new opportunities to expand partnerships, enhance customer engagement, and strengthen its position as a go-to provider of cutting-edge clinical data solutions. The company’s continued expansion of its expert advisory network reflects a strong commitment to sustainable, expert-driven innovation.
Patients’ Significance
TrialAssure plays a central role in ensuring that clinical research results are accessible, transparent, and ethically reported, which directly benefits patients by improving trust, safety, and understanding of ongoing scientific efforts. Hurley’s leadership supports the development of tools that accelerate data disclosure, protect patient privacy, and promote responsible sharing of clinical findings—key components of patient-centered research ecosystems. By enabling accurate data anonymization and timely disclosure, TrialAssure helps ensure that trial participants’ information is handled responsibly while advancing global access to critical evidence that drives improved patient outcomes and therapeutic innovation.
Policy Significance
Hurley’s appointment arrives at a time when governments and regulatory agencies are strengthening mandates around clinical trial transparency, data accessibility, and AI governance. His expertise aligns with growing policy emphasis on ethically deployed AI, standardized disclosure rules, and harmonized data-sharing frameworks. As TrialAssure continues to develop compliant, audit-ready solutions for global sponsors, Hurley’s regulatory and operational insight will help guide the company through an increasingly complex policy landscape. His involvement ensures that TrialAssure remains aligned with international transparency initiatives that elevate public trust and promote accountable research practices.
With the addition of Chris Hurley to its Advisory Leadership Team, TrialAssure reinforces its position as a leading force in clinical data transparency, AI-enabled compliance, and innovation-driven trial technologies. His deep expertise in data science, regulatory workflows, and programming strengthens TrialAssure’s mission to deliver reliable, intelligent solutions that meet the evolving needs of sponsors, regulators, and patients worldwide. As data complexity and regulatory demands continue to rise, Hurley’s guidance will play a key role in shaping the future of TrialAssure’s platforms and ensuring that clinical research remains transparent, compliant, and scientifically rigorous.
Source: TrialAssure press release
